| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Pomalidomide for Kaposi Sarcoma in People With or Without HIV (NCT01495598) | National Cancer Institute (NCI) | 2012-01-10 |
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma (NCT00923936) | National Cancer Institute (NCI) | 2009-04-23 |
| KSHV Infection in Blood Donors From Texas (NCT00006310) | The University of Texas Health Science Center at San Antonio | 1999-04-01 |
| A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma (NCT00002318) | Sequus Pharmaceuticals | |
| A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma (NCT00000769) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy (NCT00000807) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies (NCT00051597) | Seagen Inc. | |
| Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS (NCT00001059) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma (NCT00002188) | Anderson Clinical Research | |
| Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. (NCT00002167) | Clinical Solutions | |
| A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days (NCT00002136) | Daiichi Pharmaceuticals | |
| A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma (NCT00000763) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma (NCT00002259) | Lederle Laboratories | |
| A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma (NCT00002314) | Hoffmann-La Roche | |
| A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma (NCT00002439) | Anderson Clinical Research | |
| A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma (NCT00000681) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma (NCT00000695) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma (NCT00001113) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma (NCT00000687) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma (NCT00002105) | Sequus Pharmaceuticals | |
| A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma (NCT00000725) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. (NCT00002147) | Sequus Pharmaceuticals | |
| Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma (NCT00000660) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma (NCT00002262) | University of California, San Francisco | |
| A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS (NCT00000987) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma (NCT00002366) | Abbott | |
| A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma (NCT00002131) | Otsuka America Pharmaceutical | |
| A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. (NCT00002138) | Daiichi Pharmaceuticals | |
| A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3 (NCT00002185) | Agouron Pharmaceuticals | |
| Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients (NCT00002445) | Cytran | |
| A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma (NCT00000996) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma (NCT00001114) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals (NCT00002189) | Baker Norton Pharmaceuticals | |
| Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma (NCT00002226) | SUGEN | |
| A Study of Tecogalan Sodium (NCT00002342) | Daiichi Pharmaceuticals | |
| A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma (NCT00002319) | Sequus Pharmaceuticals | |
| A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma (NCT00000694) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. (NCT00002093) | Nexstar Pharmaceuticals | |
| Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders (NCT00002153) | DEKK-TEC, Inc. | |
| A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 (NCT00002137) | Daiichi Pharmaceuticals | |
| A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma (NCT00002212) | Ligand Pharmaceuticals | |